国际眼科纵览 ›› 2021, Vol. 45 ›› Issue (5): 425-430.doi: 10.3760/cma.j.issn.1673-5803.2021.05.011

• 综述 • 上一篇    下一篇

感染性葡萄膜炎玻璃体注射疗法研究进展

魏碧霞  丁琳   

  1. 新疆医科大学,乌鲁木齐 830054
  • 收稿日期:2021-01-26 出版日期:2021-10-22 发布日期:2021-10-25
  • 通讯作者: 丁琳,Email: Dinglin85600@163.com

Research progress of intravitreal injection therapy for non-infectious uveitis

Wei Bixia, Ding Lin   

  1. Xinjiang Medical University,Urumqi 830054, China
  • Received:2021-01-26 Online:2021-10-22 Published:2021-10-25
  • Contact: Ding Lin, Email: Dinglin85600@163.com

摘要: 非感染性葡萄膜炎(non-infectious uveitis,NIU)治疗目的是控制炎症,减少并发症,保护视力。NIU玻璃体注射疗法可减少全身副作用和药物频繁使用的问题,已成为全身用药的有效替代方案,且玻璃体注射途径的靶向治疗可实现NIU患者个性化精准治疗。玻璃体注射糖皮质激素(Ozurdex、Retisert、Iluvien、Yutiq、曲安奈德)、抗血管内皮生长因子(贝伐单抗、雷珠单抗、阿柏西普)、抗肿瘤坏死因子-α(阿达木单抗、英夫利昔单抗)、免疫抑制剂(西罗莫司、甲氨蝶呤、环孢素A)等可有效治疗NIU的炎症、黄斑水肿及炎性脉络膜新生血管的相关并发症。但由于缺乏对照研究,很难比较这些药物,且部分药物价格昂贵、临床试验经验较少。(国际眼科纵览,2021, 45: 425-430)

关键词: 非感染性葡萄膜炎, 玻璃体注射疗法

Abstract: Non-infectious uveitis (NIU) treatment is designed to control inflammation, reduce complications and protect vision. NIU intravitreal injection therapy can reduce systemic side effects and frequent drug use, and has become an effective alternative to systemic drug use. In addition, the intravitreal injection approach can achieve personalized and precise treatment for NIU patients. Intravitreal injection of glucocorticoid (Ozurdex, Retisert, Iluvien, Yutiq, triamcinolone acetonide), anti-vascular endothelial growth factor (bevacizumab, ranibizumab, aflibercept), anti-tumor necrosis factor-α (adalimumab, infliximab), immunosuppressants (sirolimus, methotrexate, cyclosporine A) can be effective treatment NIU inflammation and complications related to macular edema and inflammatory choroidal neovascularization. But the lack of controlled studies makes it difficult to compare these drugs, and some are expensive and have little experience in clinical trials. (Int Rev Ophthalmol, 2021, 45: 425-430)

Key words: non-infectious uveitis, intravitreous injection therapy